Discovery and Characterization of 1H-Pyrazol-5-yl-2-phenylacetamides as Novel, Non-Urea-Containing GIRK1/2 Potassium Channel Activators
- ACS Chem Neurosci. 2017 Sep 20;8(9):1873-1879. doi: 10.1021/acschemneuro.7b00217.
- 1. Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University , Nashville, Tennessee 37232, United States.
- 2. Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center , Omaha, Nebraska 68198, United States.
- 3. Department of Neuroscience and Pharmacology, Meharry Medical College , Nashville, Tennessee 37208, United States.
- 4. Sano Informed Prescribing , Franklin, Tennessee 37067, United States.
- 5. Department of Pharmacology, University of Minnesota , Minneapolis, Minnesota 55455, United States.
- 6. Department of Pharmacology, Vanderbilt University School of Medicine , Nashville, Tennessee 37232, United States.
- 7. Vanderbilt Institute of Chemical Biology, Vanderbilt University , Nashville, Tennessee 37232, United States.
The G protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) are a family of inward-rectifying potassium channels, and there is significant evidence supporting the roles of GIRKs in a number of physiological processes and as potential targets for numerous indications. Previously reported urea containing molecules as GIRK1/2 preferring activators have had significant pharmacokinetic (PK) liabilities. Here we report a novel series of 1H-pyrazolo-5-yl-2-phenylacetamides in an effort to improve upon the PK properties. This series of compounds display nanomolar potency as GIRK1/2 activators with improved brain distribution (rodent Kp > 0.6).
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Potassium ChannelResearch Areas: Neurological Disease